Managing Symptoms and Recognizing Red Flags
At a Glance
GMPPB-related limb-girdle muscular dystrophy causes weakness in the hips and shoulders that can worsen with activity and raises the risk of rhabdomyolysis, or rapid muscle breakdown. Dark urine, severe muscle pain, or sudden weakness require immediate emergency care; surgery needs anesthesia planning.
While the hallmark of GMPPB-related disease is muscle weakness, the way it shows up can change depending on your activity level and the environment. This condition often behaves like a “dual-threat” disease: it causes the muscle tissue itself to break down (muscular dystrophy) and also interferes with the way nerves talk to those muscles (neuromuscular junction defect) [1][2].
Typical Muscle Weakness
The most common symptom is proximal weakness, which means weakness in the muscles closest to the center of your body.
- Lower Limbs: Most people first notice difficulty with tasks like climbing stairs, getting up from a chair, or walking long distances [1][3].
- Upper Limbs: As the condition progresses, you may find it harder to lift your arms above your head or carry heavy objects [1].
- Sparing: Interestingly, the muscles in the face, eyes, and throat—and those used for breathing—are usually less affected in the adult-onset (LGMD) form [1]. However, this is a tendency, not a guarantee. You should always report swallowing problems, speech changes, eyelid drooping, or breathing difficulty to your doctor.
The “Fluctuating” Weakness
Unlike many other forms of muscular dystrophy, GMPPB-related disease can cause fatigable weakness [2][4]. This means your strength might be relatively good in the morning or after a nap, but it drops significantly after you use your muscles or as the day goes on [5][6]. Because this mimics a condition called Congenital Myasthenic Syndrome (CMS), some doctors may test your nerve-to-muscle communication using a test called repetitive nerve stimulation [2][5].
Emergency Red Flags: Rhabdomyolysis
People with GMPPB mutations are at a higher risk for rhabdomyolysis, a medical emergency where muscle tissue breaks down so rapidly that it releases toxic proteins into the bloodstream [7][8]. These proteins can overwhelm and damage the kidneys [9].
Seek emergency medical care immediately and do not delay transport if you experience:
- Dark Urine: Urine that looks like tea, cola, or dark beer [7][9].
- Severe Muscle Pain: Intense, widespread muscle aching or tenderness that is out of proportion to your recent activity [7][10].
- Sudden Weakness: A rapid, severe drop in strength that makes it difficult to move or stand [1].
Do not delay seeking care to try and hydrate yourself at home. Taking electrolyte drinks can be dangerous because your potassium levels may already be dangerously high from the muscle breakdown, and oral fluids may be unsafe if you have swallowing weakness. Only take small sips of water if you are fully alert, can swallow safely without choking, are not vomiting, and have been specifically told it is safe by an emergency dispatcher or clinician [9][11]. In the hospital, doctors will monitor your creatine kinase (CK) levels, kidney function, and potassium levels [10][9].
Surgery and Anesthesia Warnings
If you or your child requires surgery, you must inform the anesthesiologist about the diagnosis. Obtain a preoperative consultation with an anesthesiologist experienced in neuromuscular disease. Standard medications used during general anesthesia can cause severe reactions in people with GMPPB-related disease [1][12].
- Succinylcholine: This common “muscle relaxant” should be strictly avoided. In people with muscle disease, it can cause a massive release of potassium into the blood (hyperkalemia), which can lead to cardiac arrest [12].
- Volatile Anesthetics: Anesthetic gases (like sevoflurane or isoflurane) can trigger severe muscle breakdown (rhabdomyolysis) and should be avoided as an individualized precaution [12][13].
- Prolonged Blockade: Because of the neuromuscular junction issues mentioned earlier, paralyzing agents used in surgery may last much longer than expected, making it difficult to breathe independently after the procedure [14].
Many specialists recommend Total Intravenous Anesthesia (TIVA), which uses non-triggering medications like propofol instead of gases, and the use of reversal agents like sugammadex if muscle relaxants were necessary [12][14]. However, TIVA with propofol and sugammadex is not automatically safe or appropriate for every operation. Sugammadex only reverses certain nondepolarizing blockers and does not eliminate postoperative respiratory risk. Your anesthesiologist must create a complete drug and monitoring plan, use quantitative neuromuscular monitoring, and arrange appropriate postoperative respiratory observation [12]. Carry a medical alert card with your diagnosis and these drug warnings to present if emergency surgery cannot wait for records to be transferred.
Common questions in this guide
What symptoms are common in GMPPB-related limb-girdle muscular dystrophy?
Why does GMPPB-related weakness get worse after activity?
What signs of rhabdomyolysis mean I need emergency care?
Which anesthesia drugs are unsafe with GMPPB-related LGMD?
What should the anesthesia team plan before surgery?
Could pyridostigmine help activity-related weakness?
What tests are checked during suspected rhabdomyolysis?
Get notified when new evidence is published on GMPPB-related limb-girdle muscular dystrophy R19.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
GDP-Mannose Pyrophosphorylase B (GMPPB)-Related Disorders.
Chompoopong P, Milone M
Genes 2023; (14(2)) doi:10.3390/genes14020372.
PMID: 36833299 - 2
Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies.
Belaya K, Rodríguez Cruz PM, Liu WW, et al.
Brain : a journal of neurology 2015; (138(Pt 9)):2493-504 doi:10.1093/brain/awv185.
PMID: 26133662 - 3
Novel mutations in the C-terminal region of GMPPB causing limb-girdle muscular dystrophy overlapping with congenital myasthenic syndrome.
Luo S, Cai S, Maxwell S, et al.
Neuromuscular disorders : NMD 2017; (27(6)):557-564 doi:10.1016/j.nmd.2017.03.004.
PMID: 28433477 - 4
Lysosomal degradation of GMPPB is associated with limb-girdle muscular dystrophy type 2T.
Tian WT, Zhou HY, Zhan FX, et al.
Annals of clinical and translational neurology 2019; (6(6)):1062-1071 doi:10.1002/acn3.787.
PMID: 31211170 - 5
Familial dystroglycanopathy: same mutation, different phenotypes.
Khadilkar SV, Khade SS, Mahajan Bhanushali JP
Practical neurology 2026; doi:10.1136/pn-2026-005222.
PMID: 42248683 - 6
A founder mutation in the GMPPB gene [c.1000G > A (p.Asp334Asn)] causes a mild form of limb-girdle muscular dystrophy/congenital myasthenic syndrome (LGMD/CMS) in South Indian patients.
Polavarapu K, Mathur A, Joshi A, et al.
Neurogenetics 2021; (22(4)):271-285 doi:10.1007/s10048-021-00658-1.
PMID: 34333724 - 7
Mutations in GMPPB Presenting with Pseudometabolic Myopathy.
Panicucci C, Fiorillo C, Moro F, et al.
JIMD reports 2018; (38()):23-31 doi:10.1007/8904_2017_25.
PMID: 28456886 - 8
Two patients with GMPPB mutation: The overlapping phenotypes of limb-girdle myasthenic syndrome and limb-girdle muscular dystrophy dystroglycanopathy.
Montagnese F, Klupp E, Karampinos DC, et al.
Muscle & nerve 2017; (56(2)):334-340 doi:10.1002/mus.25485.
PMID: 27874200 - 9
A "crush" course on rhabdomyolysis: risk stratification and clinical management update for the perioperative clinician.
Cote DR, Fuentes E, Elsayes AH, et al.
Journal of anesthesia 2020; (34(4)):585-598 doi:10.1007/s00540-020-02792-w.
PMID: 32424487 - 10
Factors Associated with Acute Kidney Injury Occurrence and Prognosis in Rhabdomyolysis at the Emergency Department.
Seo JS, Yeo I, Kim C, et al.
Medicina (Kaunas, Lithuania) 2024; (60(1)) doi:10.3390/medicina60010105.
PMID: 38256366 - 11
Rhabdomyolysis - Go big or go home.
Manis T, George-Varghese B, Kashani J
The American journal of emergency medicine 2019; (37(12)):2194-2196 doi:10.1016/j.ajem.2019.03.024.
PMID: 30902360 - 12
Anaesthetic management of patients with myopathies.
Schieren M, Defosse J, Böhmer A, et al.
European journal of anaesthesiology 2017; (34(10)):641-649 doi:10.1097/EJA.0000000000000672.
PMID: 28719515 - 13
Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: A 25-year retrospective study.
Bamaga AK, Riazi S, Amburgey K, et al.
Neuromuscular disorders : NMD 2016; (26(3)):201-6.
PMID: 26951757 - 14
A Review of Muscle Relaxants in Anesthesia in Patients with Neuromuscular Disorders Including Guillain-Barré Syndrome, Myasthenia Gravis, Duchenne Muscular Dystrophy, Charcot-Marie-Tooth Disease, and Inflammatory Myopathies.
Radkowski P, Oniszczuk H, Opolska J, et al.
Medical science monitor : international medical journal of experimental and clinical research 2024; (30()):e945675 doi:10.12659/MSM.945675.
PMID: 39618072
This page is for informational purposes only and does not constitute medical advice. Your neuromuscular clinician and anesthesiologist should create an individualized plan for symptoms, emergencies, and surgery.